Tenaya Therapeutics
Tenaya Therapeutics works on 3 rare diseases tracked on Trial Friend, including Arrhythmogenic Cardiomyopathy, Familial Hypertrophic Cardiomyopathy, Peripartum Cardiomyopathy, with 4 recruiting clinical trials.
Tenaya Therapeutics is a clinical-stage biotechnology company developing gene therapies and small molecule treatments for rare genetic heart diseases. Lead programs include TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), which dosed its first patient in the RIDGE-1 Phase 1b/2 trial in November 2024.
Focus areas at Tenaya Therapeutics
As a rare disease specialist, Tenaya Therapeutics has active clinical trial programs and drug development efforts across 3 rare diseases, including Arrhythmogenic Cardiomyopathy, Familial Hypertrophic Cardiomyopathy, Peripartum Cardiomyopathy. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.
The clinical trials section below shows all active and recruiting studies sponsored by Tenaya Therapeutics, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites. The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Tenaya Therapeutics is headquartered in South San Francisco, United States, founded in 2016, publicly traded under the ticker symbol TNYA. The company dedicates its research and development resources exclusively to rare and orphan diseases, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Tenaya Therapeutics Drug Pipeline
Tenaya Therapeutics has 4 active clinical trials across 3 development stages, with 4 currently recruiting participants. Clinical trials advance through phases: Phase 1 tests safety in a small group, Phase 2 evaluates effectiveness and side effects, Phase 3 confirms benefit in a larger population, and Phase 4 monitors long-term safety after FDA approval.
Note: This pipeline includes all of Tenaya Therapeutics's active interventional trials, not only those targeting rare diseases. We show the full pipeline because a company's broader research activity, therapeutic expertise, and development infrastructure directly shape its ability to advance rare disease programs. A strong overall pipeline often signals deeper clinical operations, faster enrollment capabilities, and greater commitment to bringing new treatments to patients.
Tenaya Therapeutics Clinical Trials (4)
Active and recruiting clinical trials sponsored by Tenaya Therapeutics, sourced live from ClinicalTrials.gov. Each trial card shows the study phase, current recruitment status, conditions under investigation, study locations, eligibility criteria, and a direct link to the full ClinicalTrials.gov record. You can also download a one-page PDF summary to share with your doctor.
Note: Recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator.
FDA-Approved Drugs
Tenaya Therapeutics Trial Locations
Tenaya Therapeutics clinical trials are running at 67 sites in 8 countries. Click any country to drill down by state, city, and individual research facility. Proximity to a trial site is one of the most important factors in deciding whether to participate.
Rare Disease Focus Areas (3)
Diseases targeted by Tenaya Therapeutics's clinical trial and drug development programs
Arrhythmogenic cardiomyopathy is a rare genetic heart disease characterized by replacement of cardiac myocardium with fibrofatty tissue, particularly affecting the right ventricle. Caused by mutations...
Familial hypertrophic cardiomyopathy is a genetic heart muscle disease characterized by inappropriate left ventricular hypertrophy and diastolic dysfunction. Caused by mutations in genes encoding sarc...
Peripartum cardiomyopathy is a rare form of heart failure that develops during the last month of pregnancy or within 5 months after delivery in women with no prior history of heart disease. The heart ...
Patient Resources
Organizations and resources related to Tenaya Therapeutics's rare disease focus areas
Frequently Asked Questions About Tenaya Therapeutics
Common questions about Tenaya Therapeutics's rare disease programs, clinical trials, and treatments.